corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 9878

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: Journal Article

Calaf J, Ferrer M.
Pharmacological treatment of menopause in Spain in 2002
Clinica e Investigacion en Ginecologia y Obstetricia 2004; 30:(9):299-306


Abstract:

Rationale and goals: The treatment of menopausal consequences with estrogens is controversial. The recent publication of randomized clinical trials and new therapeutical approaches has raised our interest in evaluating the evolution of its prescription in Spain during recent years as a reflection of the perception of clinicians on this topic. Methods: We have investigated the sales of prescription products with the indication of menopausal symptoms and osteoporosis from databases generated by International Marketing Services (IMS). We have gathered the annual data between 1990 and 2002 for women aged between 45 and 64. The number of units sold have been transformed in ETY’s (estimated treatment years) and calculated the use trend for years. Results: The use of estrogens has increased steadily since 1990 (1.3%) until 2000 (7.8%) and then decreased slightly (7.4%). There has been a goegraphical distribution with a trend to decrease in use from north to south and from east to west. The utilization rates of hormone replacement therapy is lower than that in countries of a similar economical environment and annual income levels. There are no objective data to explain these differences. The therapeutical family of estrogens and similar molecules is the most prescribed during the peri and early post-menopausal period. Thereafter raloxifene and biphosphonates are predominantly prescribed. Conclusions: The prescibing patterns of hormone replacement, raloxifene and biphosphonates tend to coincide with a strategy based on quality evidences. Apparently prescription attitudes follow rational criteria and are based on clinicians objectives.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Cases of wilful misrepresentation are a rarity in medical advertising. For every advertisement in which nonexistent doctors are called on to testify or deliberately irrelevant references are bunched up in [fine print], you will find a hundred or more whose greatest offenses are unquestioning enthusiasm and the skill to communicate it.

The best defence the physician can muster against this kind of advertising is a healthy skepticism and a willingness, not always apparent in the past, to do his homework. He must cultivate a flair for spotting the logical loophole, the invalid clinical trial, the unreliable or meaningless testimonial, the unneeded improvement and the unlikely claim. Above all, he must develop greater resistance to the lure of the fashionable and the new.
- Pierre R. Garai (advertising executive) 1963